Inventor · disambiguated record
Glenn A. Meyer
Also filed as: MEYER GLENN A · MEYER GLENN ALAN
40 granted patents·7 pending applications·644 citations·filing 1991–2021
98Inventor score
Files withOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT18OSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG7ABBOTT LAB4MEYER GLENN A3ADAMAS PHARMACEUTICALS INC2
Top patents by PatentIndex Score
47 records- 0195US9801841B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2017·Granted Oct 31, 2017·13 cites·43 claims
- 0295US9655858B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2016·Granted May 23, 2017·16 cites·30 claims
- 0394US10213394B1Composition and method for treating neurological diseaseOSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG·Filed 2018·Granted Feb 26, 2019·7 cites·28 claims
- 0494US9585843B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2016·Granted Mar 7, 2017·13 cites·30 claims
- 0594US9579289B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2016·Granted Feb 28, 2017·14 cites·34 claims
- 0694US8574626B2Osmotic device containing amantadine and an osmotic saltVERGEZ JUAN A·Filed 2012·Granted Nov 5, 2013·36 cites·72 claims
- 0792US8685451B2Triple combination release multi-layered tabletTONEGUZZO FERNANDO G·Filed 2008·Granted Apr 1, 2014·34 cites·14 claims
- 0891US8252331B2Osmotic device containing amantadine and an osmotic saltMEYER GLENN A·Filed 2005·Granted Aug 28, 2012·30 cites·20 claims
- 0991US5294615ATerazosin polymorph and pharmaceutical compositionABBOTT LAB·Filed 1993·Granted Mar 15, 1994·43 cites·8 claims
- 1090US10213393B1Composition and method for treating neurological diseaseOSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOESSEGU TARSASAG·Filed 2018·Granted Feb 26, 2019·7 cites·26 claims
- 1190US9833412B2Triple combination release multi-layered tabletOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2014·Granted Dec 5, 2017·9 cites·20 claims
- 1289US10500171B2Composition and method for treating neurological diseaseOSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG·Filed 2019·Granted Dec 10, 2019·2 cites·23 claims
- 1389US5160742ASystem for delivering an active substance for sustained releaseABBOTT LAB·Filed 1991·Granted Nov 3, 1992·125 cites·40 claims
- 1488US10512617B2Composition and method for treating neurological diseaseOSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG·Filed 2019·Granted Dec 24, 2019·2 cites·29 claims
- 1588US10500172B2Composition and method for treating neurological diseaseOSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG·Filed 2019·Granted Dec 10, 2019·2 cites·29 claims
- 1686US6365180B1Oral liquid compositionsFiled 1999·Granted Apr 2, 2002·96 cites·53 claims
- 1780US6287594B1Oral liquid compositionsFiled 1999·Granted Sep 11, 2001·64 cites·8 claims
- 1878US6316020B1Pharmaceutical formulationsFiled 2000·Granted Nov 13, 2001·8 cites·15 claims
- 1978US6312723B1Pharmaceutical unit dosage formFiled 2000·Granted Nov 6, 2001·12 cites·12 claims
- 2077US10987312B2Controlled release dosage form with enhanced pharmacokineticsOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2019·Granted Apr 27, 2021·0 cites·29 claims
- 2177US10500170B2Composition and method for treating neurological diseaseOSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG·Filed 2019·Granted Dec 10, 2019·1 cites·23 claims
- 2277US6312712B1Method of improving bioavailabilityFiled 2000·Granted Nov 6, 2001·7 cites·12 claims
- 2375US11890261B2Composition and method for treating neurological diseaseADAMAS PHARMACEUTICALS INC·Filed 2021·Granted Feb 6, 2024·0 cites·18 claims
- 2474US11717483B2Controlled release dosage form with enhanced pharmacokineticsOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2021·Granted Aug 8, 2023·0 cites·16 claims
- 2574US2020129454A1Composition and method for treating neurological diseaseOSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG·Filed 2019·Application pending·0 cites
- 2673US11679088B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2021·Granted Jun 20, 2023·0 cites·30 claims
- 2773US8293799B2Osmotic device containing a venlafaxine salt and a salt having an ion in commonFELEDER ETHEL C·Filed 2004·Granted Oct 23, 2012·8 cites·30 claims
- 2873US2020129455A1Composition and method for treating neurological diseaseMEYER GLENN A·Filed 2019·Application pending·0 cites
- 2972US10987328B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2019·Granted Apr 27, 2021·0 cites·39 claims
- 3072US10532031B2Controlled release dosage form with enhanced pharmacokineticsOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2018·Granted Jan 14, 2020·0 cites·37 claims
- 3170US10471031B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2019·Granted Nov 12, 2019·0 cites·41 claims
- 3269US11090281B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2020·Granted Aug 17, 2021·0 cites·41 claims
- 3369US5599556AProlamine coatings for taste maskingABBOTT LAB·Filed 1994·Granted Feb 4, 1997·31 cites·10 claims
- 3468US10213404B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2018·Granted Feb 26, 2019·0 cites·30 claims
- 3568US10172800B2Controlled release dosage form with enhanced pharmacokineticsOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2017·Granted Jan 8, 2019·0 cites·29 claims
- 3668US5609909AProlamine coatings for taste maskingABBOTT LAB·Filed 1995·Granted Mar 11, 1997·28 cites·18 claims
- 3767US10213403B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2018·Granted Feb 26, 2019·0 cites·36 claims
- 3867US10213402B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2017·Granted Feb 26, 2019·0 cites·28 claims
- 3967US6245352B1Pharmaceutical formulationLILLY CO ELI·Filed 1999·Granted Jun 12, 2001·36 cites·14 claims
- 4066US10610505B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2018·Granted Apr 7, 2020·0 cites·30 claims
- 4164US11833121B2Composition and method for treating neurological diseaseADAMAS PHARMACEUTICALS INC·Filed 2020·Granted Dec 5, 2023·0 cites·16 claims
- 4262US10300032B2Controlled release dosage formOSMOTICA KERESKEDELMI ES SZOLGALTATO KFT·Filed 2017·Granted May 28, 2019·0 cites·26 claims
- 4358US2008175872A1Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing AcidOSMOTICA CORP·Filed 2007·Application pending·0 cites
- 4454US2007275060A1Extended release solid pharmaceutical composition containing carbidopa and levodopaOSMOTICA COSTA RICA SA·Filed 2006·Application pending·0 cites
- 4552US2019247331A1Composition and method for treating neurological diseaseOSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG·Filed 2019·Application pending·0 cites
- 4651US2007077301A1Venlafaxine osmotic device formulationMEYER GLENN A·Filed 2006·Application pending·0 cites
- 4750US2006063810A1Combination treatment for impaired motor function in parkinson's diseaseVERGEZ JUAN A·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Glenn A. Meyer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →